Literature DB >> 29481770

Amelioration effect of Egyptian sweet orange hesperidin on Ehrlich ascites carcinoma (EAC) bearing mice.

Thoria I K Donia1, Maria N Gerges1, Tarek M Mohamed2.   

Abstract

There are global increased interests to identify novel agents that can possess anti-tumor effects or maximize the anti-tumor effects of low doses for conventional anti-cancer drugs. The aim of this study was to investigate anti-tumor effects and protective role of isolated hesperidin from sweet orange on doxorubicin-induced toxicity in Ehrlich ascites carcinoma (EAC) bearing mice. Tumor cells were injected into Swiss albino mice followed by hesperidin administration either alone or in combination with doxorubicin. Biochemical parameters on serum and hepatic were measured. In addition, the effect of hesperidin on apoptotic genes (Caspase3 and Bax) and anti-apoptotic gene (Bcl2) on tumor cells were evaluated by RT- PCR. The results showed that addition of hesperidin to doxorubicin-induced higher anti-tumor responses than treatment with hesperidin or doxorubicin alone. Hesperidin and doxorubicin in combination prolonged the life span of EAC tumor-bearing mice which was associated with a decrease in the number of viable tumor cells and increases in dead tumor cells number. In addition, co-administration of hesperidin with doxorubicin ameliorated the alteration in serum ALT, AST, ALP, GGT and LDH activities, total protein, albumin, creatinine, urea and total lipids concentrations. Moreover, hesperidin alone and in combination with doxorubicin-treated group decreased hepatic, TBARS level significantly as compared with tumor bearing mice and doxorubicin treated group. In contrast, hesperidin alone and combined with doxorubicin ameliorated total antioxidant capacity, reduced glutathione level, and antioxidant enzymes activities such as GPx and CAT in liver tissues. Moreover, hesperidin induced apoptosis of tumor cells which appeared as DNA fragmentation by down-regulation of Bcl2 as anti-apoptotic gene and stimulation of Caspase3 and Bax genes expression as apoptotic genes. In conclusion, Egyptian citrus peels are a rich source of the antioxidant hesperidin. Moreover, it can ameliorate the cytotoxic effect of doxorubicin while enhancing its anti-tumor effect.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-tumor; Doxorubicin; Ehrlich ascites carcinoma; Hesperidin; Sweet orange

Mesh:

Substances:

Year:  2018        PMID: 29481770     DOI: 10.1016/j.cbi.2018.02.029

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  5 in total

1.  Influence of halloysite nanotubes on the efficiency of Asparaginase against mice Ehrlich solid carcinoma.

Authors:  B M M Baharoon; A M Shaik; Salim M El-Hamidy; Rady Eid El-Araby; Ashwaq H Batawi; Mohamed Abdel Salam
Journal:  Saudi J Biol Sci       Date:  2022-03-04       Impact factor: 4.052

2.  Flaxseed Ethanol Extracts' Antitumor, Antioxidant, and Anti-Inflammatory Potential.

Authors:  Elisabeta Ioana Chera; Raluca Maria Pop; Marcel Pârvu; Olga Sorițău; Ana Uifălean; Florinela Adriana Cătoi; Andra Cecan; Andrada Gabriela Negoescu; Patriciu Achimaș-Cadariu; Alina Elena Pârvu
Journal:  Antioxidants (Basel)       Date:  2022-04-30

3.  Nanotechnology improves the therapeutic efficacy of gemcitabine against a human hepatocellular carcinoma cell line and minimizes its in vivo side effects.

Authors:  Sawsan M A El-Sheikh; Mohamed H Khairy; Eman Osama; Mohamed M M Metwally; Azza A A Galal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-10-26       Impact factor: 3.000

Review 4.  The Role of Flavonoids as a Cardioprotective Strategy against Doxorubicin-Induced Cardiotoxicity: A Review.

Authors:  Rony Abdi Syahputra; Urip Harahap; Aminah Dalimunthe; M Pandapotan Nasution; Denny Satria
Journal:  Molecules       Date:  2022-02-15       Impact factor: 4.411

5.  Protective and Therapeutic Efficacy of Hesperidin versus Cisplatin against Ehrlich Ascites Carcinoma-Induced Renal Damage in Mice.

Authors:  Nahed Saleh; Tamer Allam; Reda M S Korany; Abdelfattah M Abdelfattah; Ahmed M Omran; Mabrouk Attia Abd Eldaim; Aziza M Hassan; Nermeen Borai El-Borai
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.